A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin...
https://pubmed.ncbi.nlm.nih.gov/32278004Actively Recruiting
Age: 18Years - 90Years
All Genders
ID05974904
Association of High-sensitivity C-reactive Protein to Albumin Ratio with Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: a Cross-sectional Study
Led by Chongqing Medical University · Updated on 2025-02-12
7000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between a new inflammatory marker called high-sensitivity C-reactive protein to albumin ratio (hsCAR) and metabolic dysfunction-associated fatty liver disease (MAFLD). This observational study aims to find out if hsCAR can help identify patients with MAFLD and whether it can detect liver fibrosis complications in these patients. The study uses data from participants in the NHANES database to explore these questions. The study evaluates participants by measuring liver steatosis and fibrosis using ultrasound-based indices. Participants are grouped based on their controlled attenuation parameter and liver stiffness measurements to compare non-MAFLD and MAFLD groups, as well as non-fibrosis and fibrosis groups. The hsCAR marker is used as an inflammatory indicator to assess disease severity across these groups. Participants undergo evaluations at baseline including controlled attenuation parameter and liver stiffness measurement to assess liver health. The study uses multivariate analyses and subgroup assessments to explore the link between hsCAR and MAFLD. The total participation involves a cross-sectional assessment using existing clinical and ultrasound data, focusing on these measurements and inflammatory markers to understand liver disease severity and fibrosis presence.
CONDITIONS
Brief Title
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Who Can Participate
Age: 18Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
- Participants from NHANES 2017-2020
- Diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD)
- Diagnosis of diabetes mellitus based on medication, HbA1c, fasting plasma glucose, or 2-hour plasma glucose
- Overweight or obesity defined as BMI 25 kg/m2 in Caucasians or 23 kg/m2 in Asians
- Presence of at least two metabolic risk abnormalities, including waist circumference thresholds, blood pressure, plasma triglycerides, HDL-cholesterol, prediabetes levels, insulin resistance, or high-sensitivity C-reactive protein levels
You will not qualify if you...
- Missing liver ultrasound data
- Incomplete clinical data
- Under 18 years old
- Having cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - At baseline
Participants undergo ultrasound and liver stiffness measurements to evaluate the severity of fatty liver and liver fibrosis.
1 visit (in-person)
Long-term Monitoring
Duration - Cross-sectional study period up to study completion
Participants are observed to assess the association between high-sensitivity C-reactive protein to albumin ratio and metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis.
No additional visits required
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000
Actively Recruiting
Loading map...
Research Team
T
Tingqiu Wang, Bachelor
Z
Zhigang Luo, Master
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Peter J Eddowes, Magali Sasso, Michael Allison...
https://pubmed.ncbi.nlm.nih.gov/30689971Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis.
Amirali Karimi, Parnian Shobeiri, Arutha Kulasinghe...
https://pubmed.ncbi.nlm.nih.gov/34745112